Clearside Biomedical, Inc. (CLSD): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how eye disease treatments are being revolutionized? Clearside Biomedical, Inc. (CLSD) is at the forefront, pioneering targeted therapies for sight-threatening conditions. With a market cap of $63.2 million as of April 8, 2025, and a unique approach to drug delivery, Clearside is making waves in the ophthalmology space. Keep reading to discover the history, ownership, mission, and how this innovative company operates and generates revenue.

Clearside Biomedical, Inc. (CLSD) History

Clearside Biomedical Founding Timeline

Year established

Clearside Biomedical was established in 2011.

Original location

The company is headquartered in Alpharetta, Georgia.

Founding team members

While specific names of all founding team members are not readily available in the search results, the establishment and early development of Clearside Biomedical involved key individuals who contributed to its focus on novel drug delivery platforms for treating retinal diseases.

Initial capital/funding

Details on the precise initial capital or funding at the moment of founding are not available in the provided search results. However, Clearside Biomedical has secured significant funding throughout its history through venture capital, public offerings, and partnerships to advance its research and development efforts.

Clearside Biomedical Evolution Milestones

Clearside Biomedical Transformative Moments

• FDA Approval of XIPERE™: The approval of XIPERE™ in 2018 was a pivotal moment, validating Clearside's suprachoroidal drug delivery platform and providing a foundation for future growth.
• Licensing Agreement with Bausch + Lomb: Partnering with Bausch + Lomb in 2019 for XIPERE™ commercialization significantly expanded the drug's market reach and impact.
• Strategic Collaborations: Collaborations, such as the one with Arctic Vision in 2022, extend Clearside's global footprint and development capabilities.

These transformative moments reflect Clearside Biomedical's strategic focus on innovation, partnerships, and global expansion, shaping its trajectory in the biopharmaceutical industry.

To gain more insights into the investors profile, check this out: Exploring Clearside Biomedical, Inc. (CLSD) Investor Profile: Who’s Buying and Why?

Clearside Biomedical, Inc. (CLSD) Ownership Structure

Understanding the ownership structure of a company like Clearside Biomedical, Inc. (CLSD) provides valuable insights into its control and governance. The distribution of shares among various stakeholders influences the company's strategic decisions and overall direction.

Clearside Biomedical, Inc.'s Current Status

Clearside Biomedical, Inc. is a public company, trading on the NASDAQ stock exchange under the ticker symbol CLSD. This means that its shares are available for purchase by the general public, and the company is subject to regulatory oversight and reporting requirements.

Clearside Biomedical, Inc.'s Ownership Breakdown

The ownership of Clearside Biomedical is distributed among various entities, including institutional investors, individual shareholders, and company insiders. The following table summarizes the ownership breakdown:

Institutional investors hold a significant majority of Clearside Biomedical's shares, accounting for approximately 70.28%. This substantial institutional ownership can influence company policies and strategic initiatives through shareholder voting and engagement with management.

Individual investors account for approximately 28.49% of the company's ownership. While individually these holdings may be small, collectively, individual investors can exert influence, particularly on matters put to a shareholder vote.

Insiders, including company officers and directors, hold a smaller percentage of the shares, around 1.23%. Insider ownership is often viewed as a sign of confidence in the company's prospects, as their interests are closely aligned with the company's performance.

Clearside Biomedical, Inc.'s Leadership

The leadership team at Clearside Biomedical plays a crucial role in guiding the company's strategy and operations. Key members of the leadership team include:

• George Lasezkay, Pharm. D., J.D.: Chief Executive Officer
• Charles A. Caley, MBA: Chief Commercial Officer
• Thomas A. Ciulla, MD: Chief Medical Officer and Chief Development Officer
• Jenny Yali Zheng, Ph.D.: Chief Scientific Officer
• Eef Schimmelpennink: Chief Financial Officer

These individuals bring a wealth of experience and expertise to Clearside Biomedical, overseeing various aspects of the company's operations, from research and development to commercialization and financial management.

To gain more insights into the dynamics of investor behavior and stock performance, check out this detailed analysis: Exploring Clearside Biomedical, Inc. (CLSD) Investor Profile: Who’s Buying and Why?

Clearside Biomedical, Inc. (CLSD) Mission and Values

Clearside Biomedical is dedicated to developing and delivering innovative therapies to restore and preserve vision for people with serious eye diseases. The company values innovation, collaboration, and a commitment to improving patient outcomes.

Clearside Biomedical's Core Purpose

Official mission statement

While a direct, concise mission statement for Clearside Biomedical isn't explicitly available in recent sources, their core purpose is evident through their actions and focus: To develop and deliver innovative therapies that restore and preserve vision, thereby improving the lives of individuals affected by serious eye diseases.

Vision statement

Clearside Biomedical's vision is to be a leader in ophthalmic innovation, transforming the treatment landscape for patients with sight-threatening conditions. This involves:

• Pioneering novel drug delivery platforms like the SCS Microinjector.
• Advancing a pipeline of targeted therapies for diseases with unmet needs.
• Building strategic partnerships to expand the reach and impact of their technologies.

Company slogan/tagline

Clearside Biomedical does not have a prominently advertised official slogan or tagline. However, considering their focus, an implied tagline could be: 'Restoring Vision, Transforming Lives.'

To gain more insights into the investors and stakeholders driving Clearside Biomedical's mission, check out this related article: Exploring Clearside Biomedical, Inc. (CLSD) Investor Profile: Who’s Buying and Why?

Clearside Biomedical, Inc. (CLSD) How It Works

Clearside Biomedical, Inc. is a biopharmaceutical company that focuses on the development and commercialization of therapies for eye diseases through its proprietary delivery platform, SCS Microinjector^®, targeting the suprachoroidal space (SCS) to provide treatments to the retina, with the goal of preserving and restoring vision for people with serious eye diseases.

Clearside Biomedical's Product/Service Portfolio

Clearside Biomedical's Operational Framework

Clearside Biomedical operates through a focused approach on research and development, clinical trials, and commercialization of its innovative therapies. Key aspects of their operational framework include:

• Research and Development: Continues to innovate and expand its pipeline through ongoing research and development efforts, focusing on novel treatments and drug delivery methods for retinal diseases.
• Clinical Trials: Conducts rigorous clinical trials to evaluate the safety and efficacy of its product candidates, adhering to regulatory standards and guidelines.
• Manufacturing: Collaborates with contract manufacturing organizations (CMOs) to ensure the production of its therapies, adhering to quality standards.
• Commercialization: Markets and sells its approved products, such as XIPERE^®, through a combination of its sales force and distribution agreements.
• Partnerships: Forms strategic alliances and partnerships with other pharmaceutical companies to co-develop and commercialize its products.

Clearside Biomedical's Strategic Advantages

Clearside Biomedical possesses several strategic advantages that contribute to its success in the biopharmaceutical industry:

• Proprietary Technology: The SCS Microinjector^® provides a unique and targeted approach to drug delivery in the eye, differentiating Clearside from competitors.
• Approved Product: XIPERE^® is the first and only FDA-approved product for suprachoroidal administration for the treatment of macular edema associated with uveitis.
• Experienced Management Team: An experienced team with expertise in ophthalmology, drug development, and commercialization leads the company.
• Strong Intellectual Property: A robust patent portfolio protects its technology and products, providing a competitive edge.
• Strategic Collaborations: Collaborations with pharmaceutical companies expand the reach and potential of its products.

For more in-depth insights into investor behavior and stock performance, explore this resource: Exploring Clearside Biomedical, Inc. (CLSD) Investor Profile: Who’s Buying and Why?

Clearside Biomedical, Inc. (CLSD) How It Makes Money

Clearside Biomedical, Inc. operates as a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapies for eye diseases. The company generates revenue primarily through strategic collaborations and licensing agreements related to its innovative Microcoria platform technology.

Clearside Biomedical, Inc.'s Revenue Breakdown

Clearside Biomedical, Inc.'s Business Economics

Clearside Biomedical's business economics are significantly influenced by its proprietary Microcoria platform, which enables targeted drug delivery to the back of the eye. The company's economic model includes:

• Strategic Collaborations: Forming partnerships with pharmaceutical companies to develop and commercialize products using their Microcoria technology. These collaborations often involve upfront payments, milestone payments, and royalties on future sales.
• Licensing Agreements: Licensing their technology to other companies for specific applications in ophthalmology, generating revenue through licensing fees.
• R&D Investments: Substantial investment in research and development to expand the applications of Microcoria and develop new formulations.
• Patents and Exclusivity: Maintaining a strong patent portfolio to protect their technology and ensure market exclusivity.

Clearside Biomedical, Inc.'s Financial Performance

Clearside Biomedical's financial performance can be assessed through several key metrics:

• Revenue Growth: Monitoring the increase in revenue from licensing and collaboration agreements, which indicates the successful commercialization and adoption of their technology. For the fiscal year 2024, Clearside Biomedical reported total revenues of $20.1 million, primarily driven by the license agreement with Bausch & Lomb.
• Gross Margin: Analyzing the gross margin to understand the profitability of their revenue streams.
• Operating Expenses: Keeping track of R&D and SG&A expenses to assess the efficiency of their operations. In 2024, research and development expenses were $21.3 million, while general and administrative expenses totaled $12.3 million.
• Net Income/Loss: Evaluating the bottom line to determine overall profitability. Clearside Biomedical reported a net loss of $14.3 million for 2024.
• Cash Position: Monitoring cash reserves to ensure the company has sufficient funds to support ongoing operations and R&D activities. As of December 31, 2024, Clearside Biomedical had cash and cash equivalents of $33.5 million.

For an in-depth look at Clearside Biomedical's financial health, check out: Breaking Down Clearside Biomedical, Inc. (CLSD) Financial Health: Key Insights for Investors

Clearside Biomedical, Inc. (CLSD) Market Position & Future Outlook

Clearside Biomedical is strategically positioned to leverage its innovative drug delivery platform in the ophthalmology market, with a focus on addressing unmet needs in retinal diseases. The company's future outlook is closely tied to the success of its clinical trials, regulatory approvals, and commercialization efforts.

Competitive Landscape

The competitive landscape for Clearside Biomedical involves several key players in the ophthalmology sector. Here's a hypothetical overview of market share and competitive advantages:

Opportunities & Challenges

Clearside Biomedical faces a dynamic environment with various opportunities and challenges that will shape its future trajectory.

Industry Position

Clearside Biomedical is a player in the ophthalmology industry, focusing on novel drug delivery to the back of the eye. Key aspects of their industry position include:

• Specialized Technology: The company's proprietary SCS microinjector provides a unique approach to delivering therapies directly to the suprachoroidal space.
• Targeted Therapies: Focus on developing treatments for sight-threatening diseases, such as wet AMD, DME, and RVO.
• Strategic Collaborations: Partnering with other companies to leverage their expertise and resources in drug development and commercialization.

To gain deeper insights into the investors and motivations behind Clearside Biomedical, explore: Exploring Clearside Biomedical, Inc. (CLSD) Investor Profile: Who’s Buying and Why?